Scholarlink

<p>We investigated the protective effects of skipjack tuna (<i>Katsuwonus pelamis</i>) bone-derived biocalcium (Bio) against dexamethasone-induced atrophy in C2C12 myotubes. Bio rescued atrophic morphology, increasing myotube diameter dose-dependently. It mitigated inflammation by suppressing nitric oxide production and the expression and concentration of proinflammatory cytokines (IL-6, TNF-α, IL-1β) significantly and dose-dependently. Bio restored protein turnover balance by downregulating MuRF1 and atrogin-1 while upregulating MTOR. At 5–20&#xa0;µg/mL, Bio downregulated total NF-κB p65, p38 mitogen-activated protein kinase (MAPK), and FoxO3a and upregulated Akt expression. Crucially, Bio dose-dependently downregulated primary-, precursor-, and mature-microRNA-29b. In Bio-treated, dexamethasone-treated C2C12 myotubes, microRNA-29b inhibitor co-transfection significantly increased myogenin and MyoD expression, whereas microRNA-29b mimic co-transfection suppressed these myogenic markers, confirming the inhibitory role of microRNA-29b. Molecular docking simulations confirmed strong binding affinities between microRNA-29b and myogenin/MyoD. These results demonstrate that Bio exerts anti-atrophy effects by disrupting the microRNA-29b-mediated block on myogenesis and modulating inflammatory responses, protein turnover, and key signaling pathways. Collectively, skipjack tuna-derived Bio shows promise as a functional food supplement for sarcopenia prevention and management.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Skipjack tuna bone derived biocalcium ameliorates C2C12 myotube atrophy through microRNA29b regulation

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月12日

查看全文
  • Sompot Jantarawong,
  • Theeraphol Senphan,
  • Chanokwanan Youngruk,
  • Nicha Thongchai,
  • Papitchaya Watcharanurak,
  • Pasjan Satrimafitrah,
  • Yuya Yamaguchi,
  • Kazuya Hasegawa,
  • Yutthana Pengjam

摘要

We investigated the protective effects of skipjack tuna (Katsuwonus pelamis) bone-derived biocalcium (Bio) against dexamethasone-induced atrophy in C2C12 myotubes. Bio rescued atrophic morphology, increasing myotube diameter dose-dependently. It mitigated inflammation by suppressing nitric oxide production and the expression and concentration of proinflammatory cytokines (IL-6, TNF-α, IL-1β) significantly and dose-dependently. Bio restored protein turnover balance by downregulating MuRF1 and atrogin-1 while upregulating MTOR. At 5–20 µg/mL, Bio downregulated total NF-κB p65, p38 mitogen-activated protein kinase (MAPK), and FoxO3a and upregulated Akt expression. Crucially, Bio dose-dependently downregulated primary-, precursor-, and mature-microRNA-29b. In Bio-treated, dexamethasone-treated C2C12 myotubes, microRNA-29b inhibitor co-transfection significantly increased myogenin and MyoD expression, whereas microRNA-29b mimic co-transfection suppressed these myogenic markers, confirming the inhibitory role of microRNA-29b. Molecular docking simulations confirmed strong binding affinities between microRNA-29b and myogenin/MyoD. These results demonstrate that Bio exerts anti-atrophy effects by disrupting the microRNA-29b-mediated block on myogenesis and modulating inflammatory responses, protein turnover, and key signaling pathways. Collectively, skipjack tuna-derived Bio shows promise as a functional food supplement for sarcopenia prevention and management.